Synthesis of the Antibiotic Peptide, Olenamidonin B
| dc.contributor.author | Charette, Victor | |
| dc.date.accessioned | 2026-08-26T17:31:50Z | |
| dc.date.issued | 2026-08-26 | |
| dc.date.submitted | 2026-08-24 | |
| dc.description.abstract | The increase in antibiotic resistance among pathogenic human bacteria poses an imminent threat to human life and the practice of modern medicine. In particular, bacteria of the genus Enterococci posses an aptitude for survival in the highly sterilized environments of hospitals where they are capable of causing life threatening infections. These bacteria are inherently resistant to many antibiotics and sanitization techniques. More concerningly, they have quickly acquired antibiotic resistance to several highly potent, last resort antibiotics. As a result, the development of antibiotic agents which are effective against multidrug-resistant enterococci is considered a high priority. Herein we describe our efforts to synthesize and study what we believe to be one such promising antibiotic, the cyclic lipopeptide olenamidonin B. The olenamidonins (and several related peptides) have been discovered and characterized over the last 30 years however; their mechanism of action and antibiotic potential are unknown. Before further studies are possible, a reliable synthetic route needed to be developed to access these peptides and their analogs in sufficient quantities. Thus, the objective of this project was to achieve a total synthesis of one member of the family, olenamidonin B. In Chapter 2 we described our efforts to synthesize a lipidated (E)-dehydro-β-alanine building block required for the synthesize of the lipopeptide. We developed a suitable synthesis based on a 1,4-addition of an amide to an ynone which provided the desired (E)-isomer with high selectivity and good yields. In Chapter 3 we describe our efforts to synthesize the cyclic lipopeptide itself. Although solid-phase peptide synthesis could be used to easily generate the peptide component, the late installation of the dimethyl-4-imidazolidinone was problematic for the solubility of the peptide and its early installation could not be achieved. Abandoning this approach, we successfully developed a Fmoc/Alloc protected solution-phase strategy which could be used to synthesize the peptide component and introduce the dimethyl-4-imidazolidinone early. A number of other protecting group strategies were attempted but were incompatible with the 4-imidazolidinone in some way. We completed the synthesis of olenamidonin B with the installation of the lipidated (E)-dehydro-β-alanine building block in an overall 13% yield over 14 steps. Finally, we evaluated the activity of the peptide against various strains of antibiotic resistant and susceptible bacteria which confirmed the activity of this natural product. | |
| dc.identifier.uri | https://hdl.handle.net/10012/24065 | |
| dc.language.iso | en | |
| dc.pending | false | |
| dc.publisher | University of Waterloo | en |
| dc.subject | antibiotic | |
| dc.subject | peptide | |
| dc.subject | lipopeptide | |
| dc.subject | total synthesis | |
| dc.subject | peptide synthesis | |
| dc.title | Synthesis of the Antibiotic Peptide, Olenamidonin B | |
| dc.type | Master Thesis | |
| uws-etd.degree | Master of Science | |
| uws-etd.degree.department | Chemistry | |
| uws-etd.degree.discipline | Chemistry | |
| uws-etd.degree.grantor | University of Waterloo | en |
| uws-etd.embargo.terms | 1 year | |
| uws.contributor.advisor | Taylor, Scott | |
| uws.contributor.affiliation1 | Faculty of Science | |
| uws.peerReviewStatus | Unreviewed | en |
| uws.published.city | Waterloo | en |
| uws.published.country | Canada | en |
| uws.published.province | Ontario | en |
| uws.scholarLevel | Graduate | en |
| uws.typeOfResource | Text | en |